Results from the RAPIDO phase III multicenter, randomized, open-label trial break away from the two decades-long mainstay of standard of…
News just in, Principal Investigator of our Gynecological Malignancies Group, Ana Oaknin, has once again been recognized for her global…
Barcelona, November 26, 2020.- Despite recent progress in rendering treatments more precise against advanced prostate cancer –largely driven by genomic sequencing…
Barcelona, November 18th, 2020.- Published today, Clarivate’s Web of Science has revealed its annual and global #HighlyCited2020 researchers list. Featuring among the world’s…
Launching this coming Thursday 19 November, the European Society for Medical Oncology (ESMO) and World Health Organization’s International Agency for…
February 04, 2021 will not only celebrate World Cancer Day’s 21st birthday but also the final year of its ‘I…
Movember, celebrated globally throughout the month of November, was established back in 2003 by a few friends over a beer…
The number 25 is the focus of the cover of our newly launched Scientific Report 2019; a VHIO time bar…
Results from a proof-of-concept study led by Joan Seoane show the promise of cerebrospinal fluid as liquid biopsy for the…
Vall d’Hebron has participated in the first Phase I clinical trial for iadademstat, a new potent and selective LSD1 inhibitor…
Preliminary results from the multicenter, nonrandomized GARNET phase I study reported this month in JAMA Oncology*, show promise of a…
For the first time, an immunotherapy treatment achieves results in patients with neuroendocrine tumours, increasing survival at 9 months from…
